The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study reporting one in eight Americans has taken or is currently using the drugs to ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.